In exchange for $165 million, Biogen now has access to zorevunersen, a potential first-of-its-kind treatment for Dravet ...

The company raised $200 million after early findings hinted its therapy could be more potent than others like it, including Sarepta Therapeutics’ Elevidys.

Penmenvy, which protects against five common types of disease-causing bacteria, is cleared for use in people aged 10 through ...

“We recognize that those with rare diseases often have complex needs that go unmet by traditional assistance,” said Green.